Drug Dev
Acesion tackles atrial fibrillation through SK channel inhibition
Acesion Pharma is focusing on SK channel inhibition to develop safer and more effective drugs to treat and prevent atrial fibrillation. During BIO-Europe Spring 2018, Acesion CEO Frans Wuite described to Scrip his partnering and financing ambitions for the lead program which is entering Phase I testing.